Different susceptibility of coagulase-positive and coagulase-negative staphylococci to ciprofloxacin.
Ciprofloxacin susceptibility was evaluated in 573 clinical staphylococcal isolates (Staphylococcus aureus 230, methicillin-resistant (MR) 36%; coagulase-negative strains 343, MR 66%) collected from 1989 to 1995. Resistance to ciprofloxacin for MR Staphylococcus aureus was 25% until 1991 when ciprofloxacin was introduced into the hospital formulary, and rose progressively to 90% in 1994-1995. MR Staphylococcus haemolyticus showed a ciprofloxacin resistance of 46% until 1991 and of 73% from 1992 to 1995. In contrast MR Staphylococcus epidermidis and other coagulase-negative strains showed a constant susceptibility to this agent (80%). Ciprofloxacin has limited usefulness against MR Staphylococcus aureus but can be still used to treat Staphylococcus epidermidis infections.
Institute of Medical Therapy, Second University of Naples, Italy.
R
R
Utili
M F
MF
Tripodi
P
P
Rosario
A
A
Andreana
A
A
Locatelli
A
A
Rambaldi
A
A
Florio
D002939:Ciprofloxacin / Q000494:pharmacology*; D003030:Coagulase / Q000378:metabolism; D003428:Cross Infection / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D006801:Humans; D007558:Italy; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects* / Q000201:enzymology; D013211:Staphylococcus aureus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects; D013997:Time Factors
D003030:Coagulase; D002939:Ciprofloxacin